PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19139808-11	2009	CONCLUSIONS: These results suggest that an early retreatment with leukocyte IFN-alpha may be a safe and valid therapeutic option among difficult-to-treat HCV cirrhotic patients who cannot tolerate PEG-IFNs.	peg-ifns	197-205	interferon alpha 1	Homo sapiens	76-85	
19649689-4	2009	Accordingly, we evaluated the safety and efficacy of Le-IFN-alpha in patients intolerant to peg-IFNs.	peg-ifns	92-100	interferon alpha 1	Homo sapiens	56-59	
19649689-16	2009	The data indicate that Le-IFN-alpha plus ribavirin is a useful and effective treatment for CHC patients who are intolerant to peg-IFNs.	peg-ifns	126-134	interferon alpha 1	Homo sapiens	26-29	
25831972-7	2015	RESULTS: A subset of patients suffering from pegylated IFN-alpha-associated exanthemas displayed positive intradermal tests to PEG-IFNs but not to conventional IFN (11/22).	peg-ifns	127-135	interferon alpha 1	Homo sapiens	55-64	
12739994-8	2003	Both PEG-IFNs are given by a once-weekly injection and as monotherapy, they are more effective than standard IFN-alpha.	peg-ifns	5-13	interferon alpha 1	Homo sapiens	109-118